Login to Your Account

NewCo News

iTeos' Small-Molecule Approach Adds to Immunotherapy Arsenal

By Jennifer Boggs
Managing Editor

Thursday, May 31, 2012
Nearly 20 years of work in cancer immunotherapy finally scored two big regulatory wins in recent years, with the approvals of Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) and Bristol-Myers Squibb Co.'s melanoma drug Yervoy (ipilimumab), but there is plenty of room for new approaches before the immunotherapy space reaches its full potential.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription